Neurodegenerative Disease Treatment with Nanozymes

Neurodegenerative diseases are a class of chronic progressive neurological diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), Amyotrophic lateral Sclerosis (ALS), etc. The common feature of these diseases is chronic, degenerative degeneration and cell loss of nerve cells in different regions of brain tissue. Therefore, nanozyme drugs have been widely used because they can improve physical and chemical properties, increase stability and tissue distribution, and improve the targeting of functional organs.

Creative Enzymes is a leading provider of comprehensive, high-quality services for nanozymes. We provide nanozymes for research purposes to customers worldwide in the field of neurodegenerative disease treatment. We look forward to working with our customers to discover the secrets of life sciences.

Alzheimer's Disease Treatment with Nanozymes

• Alzheimer's disease is the most common type of senile dementia, which seriously harms the health and quality of life of the elderly.

Fig. 1 Conceptual map of Alzheimer's disease.

• AD is a pathological process caused by genetic factors, environmental factors and metabolic factors. The aggregation of β-amyloid (Aβ), abnormal phosphorylation of Tau, excessive accumulation of metal in the brain and decreased level of acetylcholine (ACh) all play important roles in the pathogenesis of AD.
• Creative Enzymes provides varieties of nanozymes for treating AD, mainly including cerium oxide, iron oxide and others. The application of nanozymes in the treatment of AD can not only carry drugs across the blood-brain barrier, improve the therapeutic effect, but also help to maintain the biological activity of drugs.

Parkinson's Disease Treatment with Nanozymes

• Parkinson's Disease (PD) is a chronic progressive movement disorder. The pathological changes are mainly a severe deficiency of dopaminergic nerve cells in the substantia nigra pars compacta, resulting in a decrease of dopamine transmitters in the substantia nigra and striatum.

Fig. 2 Conceptual map of Parkinson’s disease.

• Because dopamine cannot cross the blood-brain barrier into brain tissue, the most basic drug for PD treatment is levodopa (LDA), which is the precursor of dopamine.
• Nanozymes have shown the ability to alleviate oxidative stress and inflammation directly, and to overcome barriers in passage across the blood brain barrier (BBB), although the specific mechanism for delivery across the BBB varies and has not yet been fully elucidated.
• Creative Enzymes provides varieties of nanozymes for treating PD, mainly including manganous-manganic oxide, copper oxide, iron oxide and others.

Creative Enzymes provides fast turnaround, high quality services at competitive prices for customers worldwide. Our advanced technical platforms can help our clients solve the problems they may encounter in research based on years of experience. If you are interested in our services or have any questions, please feel free to contact us or make an online inquiry.